Heard: Valeant Gives Investors Headaches

2/29/2016 2:11PM     

Embattled pharmaceutical giant Valeant gave investors a bit of headache as the company cancelled an earnings call and withdrew guidance. WSJ 'Heard on the Street' columnist Charley Grant joins Tanya Rivero with analysis for investors. Photo: Bloomberg